VolitionRx Limited's (NYSEAMERICAN:VNRX) president and CEO Cameron Reynolds recaps on what he describes as a year of 'very strong progress' in assay and platform development with its Nu.Q Capture program and epigenetic toolkit Nu.Q Vet.
Heading into 2020, Reynolds says the company's well placed to meet its key milestones - one of which is to advance its large-scale colorectal and lung cancer trials in Europe, Asia and the U.S.